PTC Therapeutics saw the highest growth of 0.99% in patent filings in April and 1.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of PTC Therapeutics‘s patent filings and grants. Buy the databook here.
PTC Therapeutics has been focused on protecting inventions in European Patent Office(EPO) with eight publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 17% filings and 30% grants. The European Patent Office(EPO), United States(US), South Korea(KR), and Australia(AU) patent Office are among the top ten patent offices where PTC Therapeutics is filings its patents. Among the top granted patent authorities, PTC Therapeutics has 30% of its grants in European Patent Office(EPO), 10% in United States(US) and 10% in Australia(AU).
Roche could be the strongest competitor for PTC Therapeutics
Patents related to rare diseases and Covid-19 lead PTC Therapeutics's portfolio
PTC Therapeutics has the highest number of patents in rare diseases followed by, Covid-19 and health & wellness. For rare diseases, nearly 80% of patents were filed and 33% of patents were granted in Q2 2024.
Petrochemicals related patents lead PTC Therapeutics portfolio followed by tauopathies, and autism spectrum disorder (asd)
PTC Therapeutics has highest number of patents in petrochemicals followed by tauopathies, autism spectrum disorder (asd), liver diseases, and coronavirus disease 2019 (covid-19).
For comprehensive analysis of PTC Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.